Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer

Evan R. Ransom; Jason M. Leibowitz; Cathy Ma; Kanchan Puttaswamy; Andrea Troxel; William Lee; Michael Feldman; Marcia S. Brose

doi:10.1002/lary.21231

Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer

Evan R. Ransom, Jason M. Leibowitz, Cathy Ma, Kanchan Puttaswamy, Andrea Troxel, William Lee, Michael Feldman, Marcia S. Brose

Research output: Contribution to journal › Article

Abstract

Objectives: To describe a new technique for assaying effects of antitumor therapeutics over time. Study Design: Tumor tissue samples were taken from a Phase II clinical trial. A method for quantification of immuno-histochemistry (IHC) was developed using a computer algorithm designed to measure staining levels spectrographically. Phospho- ERK was selected as the tumor marker for this demonstration. Results: Average nuclear DAB intensities were 846.972 (pre-treatment) and 229.249 (on-treatment). Staining intensity frequency distribution curves generated showed statistically distinct distributions, both confirming and quantifying the decreased presence of phospho-ERK in the on-treatment sample. Conclusions: A novel technique for quantification of IHC is presented. This process can be used to delineate specific cellularlevel responses to targeted anti-tumor therapeutics.

Original language	English (US)
Pages (from-to)	S47
Journal	Laryngoscope
Volume	120
Issue number	SUPPL. 3
DOIs	https://doi.org/10.1002/lary.21231
State	Published - Oct 1 2010
Externally published	Yes

Fingerprint

ASJC Scopus subject areas

Otorhinolaryngology

Cite this

Ransom, E. R., Leibowitz, J. M., Ma, C., Puttaswamy, K., Troxel, A., Lee, W., Feldman, M., & Brose, M. S. (2010). Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer. Laryngoscope, 120(SUPPL. 3), S47. https://doi.org/10.1002/lary.21231

Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer. / Ransom, Evan R.; Leibowitz, Jason M.; Ma, Cathy; Puttaswamy, Kanchan; Troxel, Andrea; Lee, William; Feldman, Michael; Brose, Marcia S.

In: Laryngoscope, Vol. 120, No. SUPPL. 3, 01.10.2010, p. S47.

Research output: Contribution to journal › Article

@article{6e77bf3866274de9bb9a5bcbbeb99459,

title = "Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer",

abstract = "Objectives: To describe a new technique for assaying effects of antitumor therapeutics over time. Study Design: Tumor tissue samples were taken from a Phase II clinical trial. A method for quantification of immuno-histochemistry (IHC) was developed using a computer algorithm designed to measure staining levels spectrographically. Phospho- ERK was selected as the tumor marker for this demonstration. Results: Average nuclear DAB intensities were 846.972 (pre-treatment) and 229.249 (on-treatment). Staining intensity frequency distribution curves generated showed statistically distinct distributions, both confirming and quantifying the decreased presence of phospho-ERK in the on-treatment sample. Conclusions: A novel technique for quantification of IHC is presented. This process can be used to delineate specific cellularlevel responses to targeted anti-tumor therapeutics.",

author = "Ransom, {Evan R.} and Leibowitz, {Jason M.} and Cathy Ma and Kanchan Puttaswamy and Andrea Troxel and William Lee and Michael Feldman and Brose, {Marcia S.}",

year = "2010",

month = oct,

day = "1",

doi = "10.1002/lary.21231",

language = "English (US)",

volume = "120",

pages = "S47",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "Wiley-Blackwell",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Quantified immunohistochemistry demonstrates cellular level targets of an oral multikinase inhibitor in metastatic thyroid cancer

AU - Ransom, Evan R.

AU - Leibowitz, Jason M.

AU - Ma, Cathy

AU - Puttaswamy, Kanchan

AU - Troxel, Andrea

AU - Lee, William

AU - Feldman, Michael

AU - Brose, Marcia S.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Objectives: To describe a new technique for assaying effects of antitumor therapeutics over time. Study Design: Tumor tissue samples were taken from a Phase II clinical trial. A method for quantification of immuno-histochemistry (IHC) was developed using a computer algorithm designed to measure staining levels spectrographically. Phospho- ERK was selected as the tumor marker for this demonstration. Results: Average nuclear DAB intensities were 846.972 (pre-treatment) and 229.249 (on-treatment). Staining intensity frequency distribution curves generated showed statistically distinct distributions, both confirming and quantifying the decreased presence of phospho-ERK in the on-treatment sample. Conclusions: A novel technique for quantification of IHC is presented. This process can be used to delineate specific cellularlevel responses to targeted anti-tumor therapeutics.

AB - Objectives: To describe a new technique for assaying effects of antitumor therapeutics over time. Study Design: Tumor tissue samples were taken from a Phase II clinical trial. A method for quantification of immuno-histochemistry (IHC) was developed using a computer algorithm designed to measure staining levels spectrographically. Phospho- ERK was selected as the tumor marker for this demonstration. Results: Average nuclear DAB intensities were 846.972 (pre-treatment) and 229.249 (on-treatment). Staining intensity frequency distribution curves generated showed statistically distinct distributions, both confirming and quantifying the decreased presence of phospho-ERK in the on-treatment sample. Conclusions: A novel technique for quantification of IHC is presented. This process can be used to delineate specific cellularlevel responses to targeted anti-tumor therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=78651434009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651434009&partnerID=8YFLogxK

U2 - 10.1002/lary.21231

DO - 10.1002/lary.21231

M3 - Article

AN - SCOPUS:78651434009

VL - 120

SP - S47

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - SUPPL. 3

ER -

Access to Document

10.1002/lary.21231